KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2026)

AbCellera Biologics filings provide 7 years of Capital Expenditures readings, the most recent being $3.8 million for Q1 2026.

  • Quarterly Capital Expenditures fell 63.98% to $3.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36.0 million through Mar 2026, down 44.57% year-over-year, with the annual reading at $42.8 million for FY2025, 45.44% down from the prior year.
  • Capital Expenditures hit $3.8 million in Q1 2026 for AbCellera Biologics, down from $9.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $31.3 million in Q2 2022 and bottomed at $3.8 million in Q1 2026.
  • Average Capital Expenditures over 5 years is $16.0 million, with a median of $14.5 million recorded in 2022.
  • The largest annual shift saw Capital Expenditures skyrocketed 297.78% in 2022 before it crashed 63.98% in 2026.
  • AbCellera Biologics' Capital Expenditures stood at $12.3 million in 2022, then grew by 17.04% to $14.4 million in 2023, then grew by 8.31% to $15.6 million in 2024, then crashed by 37.02% to $9.8 million in 2025, then crashed by 61.08% to $3.8 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Capital Expenditures are $3.8 million (Q1 2026), $9.8 million (Q4 2025), and $8.9 million (Q3 2025).